Published in Biol Psychiatry on April 03, 2006
Dopamine D2 receptor levels in striatum, thalamus, substantia nigra, limbic regions, and cortex in schizophrenic subjects. Biol Psychiatry (2009) 1.18
Thinking outside a less intact box: thalamic dopamine D2 receptor densities are negatively related to psychometric creativity in healthy individuals. PLoS One (2010) 1.03
Striatal and extrastriatal dopamine D2/D3 receptors in schizophrenia evaluated with [18F]fallypride positron emission tomography. Biol Psychiatry (2010) 0.97
The neurobiology and treatment of first-episode schizophrenia. Mol Psychiatry (2014) 0.93
Pathway-Specific Dopamine Abnormalities in Schizophrenia. Biol Psychiatry (2016) 0.83
Structural brain correlates of sensorimotor gating in antipsychotic-naive men with first-episode schizophrenia. J Psychiatry Neurosci (2013) 0.83
Brain connectivity studies in schizophrenia: unravelling the effects of antipsychotics. Curr Neuropharmacol (2012) 0.83
Striatal D(2/3) Binding Potential Values in Drug-Naïve First-Episode Schizophrenia Patients Correlate With Treatment Outcome. Schizophr Bull (2015) 0.81
Imaging-based neurochemistry in schizophrenia: a systematic review and implications for dysfunctional long-term potentiation. Schizophr Bull (2014) 0.81
Association between Serotonin-Related Polymorphisms in 5HT2A, TPH1, TPH2 Genes and Bipolar Disorder in Korean Population. Psychiatry Investig (2010) 0.80
The dopamine D3 receptor gene and posttraumatic stress disorder. J Trauma Stress (2014) 0.79
Dopamine D2 and D3 binding in people at clinical high risk for schizophrenia, antipsychotic-naive patients and healthy controls while performing a cognitive task. J Psychiatry Neurosci (2013) 0.79
How have developments in molecular imaging techniques furthered schizophrenia research? Imaging Med (2009) 0.77
Increasing endocannabinoid levels in the ventral pallidum restore aberrant dopamine neuron activity in the subchronic PCP rodent model of schizophrenia. Int J Neuropsychopharmacol (2014) 0.76
18F-fallypride binding potential in patients with schizophrenia compared to healthy controls. Schizophr Res (2010) 0.76
Dexamphetamine effects on prepulse inhibition (PPI) and startle in healthy volunteers. Psychopharmacology (Berl) (2013) 0.76
Frontal D2/3 Receptor Availability in Schizophrenia Patients Before and After Their First Antipsychotic Treatment: Relation to Cognitive Functions and Psychopathology. Int J Neuropsychopharmacol (2016) 0.75
Theranostic Biomarkers for Schizophrenia. Int J Mol Sci (2017) 0.75
[Medical concepts require content]. Ugeskr Laeger (2005) 2.91
MR-based automatic delineation of volumes of interest in human brain PET images using probability maps. Neuroimage (2004) 2.07
Evaluation of the Serotonin Transporter Ligand 123I-ADAM for SPECT Studies on Humans. J Nucl Med (2008) 1.60
Integrated software for the analysis of brain PET/SPECT studies with partial-volume-effect correction. J Nucl Med (2004) 1.56
Preclinical safety assessment of the 5-HT2A receptor agonist PET radioligand [ 11C]Cimbi-36. Mol Imaging Biol (2013) 1.25
Integrated treatment of first-episode psychosis: effect of treatment on family burden: OPUS trial. Br J Psychiatry Suppl (2005) 1.16
Frontolimbic serotonin 2A receptor binding in healthy subjects is associated with personality risk factors for affective disorder. Biol Psychiatry (2007) 1.15
Cluster analysis in kinetic modelling of the brain: a noninvasive alternative to arterial sampling. Neuroimage (2004) 1.14
Hemodynamic and neuroendocrine responses to changes in sodium intake in compensated heart failure. Am J Physiol Regul Integr Comp Physiol (2005) 1.12
Basal ganglia volumes in drug-naive first-episode schizophrenia patients before and after short-term treatment with either a typical or an atypical antipsychotic drug. Psychiatry Res (2007) 1.11
[123I]epidepride binding to cerebellar dopamine D2/D3 receptors is displaceable: implications for the use of cerebellum as a reference region. Neuroimage (2006) 1.06
The postnatal development of neocortical neurons and glial cells in the Göttingen minipig and the domestic pig brain. J Exp Biol (2006) 1.04
Hippocampal and caudate volume reductions in antipsychotic-naive first-episode schizophrenia. J Psychiatry Neurosci (2010) 1.03
A database of [(18)F]-altanserin binding to 5-HT(2A) receptors in normal volunteers: normative data and relationship to physiological and demographic variables. Neuroimage (2004) 1.03
Methods for motion correction evaluation using 18F-FDG human brain scans on a high-resolution PET scanner. J Nucl Med (2012) 1.02
Drug-induced mild therapeutic hypothermia obtained by administration of a transient receptor potential vanilloid type 1 agonist. BMC Cardiovasc Disord (2010) 0.99
Brain imaging of serotonin 4 receptors in humans with [11C]SB207145-PET. Neuroimage (2010) 0.98
Psychiatric emergency outreach: a report on the first 2 years of functioning in Copenhagen. Nord J Psychiatry (2002) 0.98
Decreased frontal serotonin2A receptor binding in antipsychotic-naive patients with first-episode schizophrenia. Arch Gen Psychiatry (2010) 0.98
"Central command" and insular activation during attempted foot lifting in paraplegic humans. Hum Brain Mapp (2005) 0.98
Quantification of 5-HT2A receptors in the human brain using [18F]altanserin-PET and the bolus/infusion approach. J Cereb Blood Flow Metab (2003) 0.98
The relationship of needs and quality of life in persons with schizophrenia living in the community. A Nordic multi-center study. Nord J Psychiatry (2003) 0.97
Dopa-responsive dystonia and early-onset Parkinson's disease in a patient with GTP cyclohydrolase I deficiency? Mov Disord (2006) 0.96
Serotonin2A receptor blockade and clinical effect in first-episode schizophrenia patients treated with quetiapine. Psychopharmacology (Berl) (2010) 0.96
Patients with obsessive-compulsive disorder have increased 5-HT2A receptor binding in the caudate nuclei. Int J Neuropsychopharmacol (2005) 0.95
Progressive striatal and hippocampal volume loss in initially antipsychotic-naive, first-episode schizophrenia patients treated with quetiapine: relationship to dose and symptoms. Int J Neuropsychopharmacol (2010) 0.94
The personality trait openness is related to cerebral 5-HTT levels. Neuroimage (2008) 0.94
Automatic semi-quantification of [123I]FP-CIT SPECT scans in healthy volunteers using BasGan version 2: results from the ENC-DAT database. Eur J Nucl Med Mol Imaging (2012) 0.93
Sensorimotor gating and habituation in antipsychotic-naive, first-episode schizophrenia patients before and after 6 months' treatment with quetiapine. Int J Neuropsychopharmacol (2010) 0.93
Missense dopamine transporter mutations associate with adult parkinsonism and ADHD. J Clin Invest (2014) 0.92
Kinetic modeling of 11C-SB207145 binding to 5-HT4 receptors in the human brain in vivo. J Nucl Med (2009) 0.92
Assessment of in vivo MR imaging compared to physical sections in vitro--a quantitative study of brain volumes using stereology. Neuroimage (2005) 0.91
A nonlinear relationship between cerebral serotonin transporter and 5-HT(2A) receptor binding: an in vivo molecular imaging study in humans. J Neurosci (2010) 0.90
No change in [¹¹C]CUMI-101 binding to 5-HT(1A) receptors after intravenous citalopram in human. Synapse (2012) 0.89
No significant association of the 5' end of neuregulin 1 and schizophrenia in a large Danish sample. Schizophr Res (2006) 0.88
The 5-HT4 receptor levels in hippocampus correlates inversely with memory test performance in humans. Hum Brain Mapp (2012) 0.87
Cluster analysis of activity-time series in motor learning. Hum Brain Mapp (2002) 0.87
In vivo imaging of cerebral serotonin transporter and serotonin(2A) receptor binding in 3,4-methylenedioxymethamphetamine (MDMA or "ecstasy") and hallucinogen users. Arch Gen Psychiatry (2011) 0.87
Severe and rapidly progressing cognitive phenotype in a SCA17-family with only marginally expanded CAG/CAA repeats in the TATA-box binding protein gene: a case report. BMC Neurol (2012) 0.87
Attenuation correction for the HRRT PET-scanner using transmission scatter correction and total variation regularization. IEEE Trans Med Imaging (2013) 0.87
Spontaneous object recognition in the Göttingen minipig. Neural Plast (2002) 0.86
Familial risk for mood disorder and the personality risk factor, neuroticism, interact in their association with frontolimbic serotonin 2A receptor binding. Neuropsychopharmacology (2009) 0.85
Serotonin 2A receptor antagonists for treatment of schizophrenia. Expert Opin Investig Drugs (2011) 0.85
Age and sex effects on 5-HT(4) receptors in the human brain: a [(11)C]SB207145 PET study. J Cereb Blood Flow Metab (2011) 0.85
Cognitive effects of six months of treatment with quetiapine in antipsychotic-naïve first-episode schizophrenia. Psychiatry Res (2010) 0.85
Impaired temporoparietal deactivation with working memory load in antipsychotic-naïve patients with first-episode schizophrenia. World J Biol Psychiatry (2011) 0.85
The prefrontal cortex in the Göttingen minipig brain defined by neural projection criteria and cytoarchitecture. Brain Res Bull (2006) 0.85
Effects of low-dose risperidone and low-dose zuclopenthixol on cognitive functions in first-episode drug-naive schizophrenic patients. CNS Spectr (2004) 0.85
Increased urinary orosomucoid excretion is not related to impaired renal function in patients with type 2 diabetes. J Diabetes Complications (2008) 0.84
Longitudinal assessment of cerebral 5-HT2A receptors in healthy elderly volunteers: an [18F]-altanserin PET study. Eur J Nucl Med Mol Imaging (2008) 0.84
Quantification of 123I-PE2I binding to dopamine transporter with SPECT after bolus and bolus/infusion. J Nucl Med (2005) 0.84
High familial risk for mood disorder is associated with low dorsolateral prefrontal cortex serotonin transporter binding. Neuroimage (2009) 0.84
The 5-HT2A receptor binding pattern in the human brain is strongly genetically determined. Neuroimage (2007) 0.83
Structural brain correlates of sensorimotor gating in antipsychotic-naive men with first-episode schizophrenia. J Psychiatry Neurosci (2013) 0.83
P50 suppression and its neural generators in antipsychotic-naive first-episode schizophrenia before and after 6 months of quetiapine treatment. Schizophr Bull (2012) 0.83
Reproducibility of 5-HT2A receptor measurements and sample size estimations with [18F]altanserin PET using a bolus/infusion approach. Eur J Nucl Med Mol Imaging (2006) 0.83
Regional activation of the human medial temporal lobe during intentional encoding of objects and positions. Neuroimage (2009) 0.83
Association between the CCR5 32-bp deletion allele and late onset of schizophrenia. Am J Psychiatry (2006) 0.83
Binding characteristics of the 5-HT2A receptor antagonists altanserin and MDL 100907. Synapse (2005) 0.83
Increased susceptibility to cardiovascular effects of dihydrocapcaicin in resuscitated rats. Cardiovascular effects of dihydrocapsaicin. BMC Cardiovasc Disord (2010) 0.83
Striatal dopamine transporter binding does not correlate with clinical severity in dementia with Lewy bodies. J Nucl Med (2013) 0.83
Relationship of frontal D(2/3) binding potentials to cognition: a study of antipsychotic-naive schizophrenia patients. Int J Neuropsychopharmacol (2012) 0.82
Reproducibility of [123I]PE2I binding to dopamine transporters with SPECT. Eur J Nucl Med Mol Imaging (2006) 0.82
(18)F-FDG PET/CT in a rare case of Stewart-Treves syndrome: future implications and diagnostic considerations. Lymphat Res Biol (2011) 0.82
Clinical impact of diagnostic SPET investigations with a dopamine re-uptake ligand. Eur J Nucl Med Mol Imaging (2002) 0.82
BDNF Val66met and 5-HTTLPR polymorphisms predict a human in vivo marker for brain serotonin levels. Hum Brain Mapp (2014) 0.81
Cognitive function is related to fronto-striatal serotonin transporter levels--a brain PET study in young healthy subjects. Psychopharmacology (Berl) (2010) 0.81
Prepulse inhibition in patients with Alzheimer's disease. Neurobiol Aging (2004) 0.81
Validation of a method for accurate and highly reproducible quantification of brain dopamine transporter SPECT studies. J Nucl Med Technol (2011) 0.80
Acquisition of visually guided conditional associative tasks in Göttingen minipigs. Behav Processes (2005) 0.80
MRI-guided region-of-interest delineation is comparable to manual delineation in dopamine transporter SPECT quantification in patients: a reproducibility study. J Nucl Med Technol (2010) 0.79
Discriminations, reversals, and extra-dimensional shifts in the Göttingen minipig. Behav Processes (2004) 0.79
Cerebral 5-HT2A receptor and serotonin transporter binding in humans are not affected by the val66met BDNF polymorphism status or blood BDNF levels. J Cereb Blood Flow Metab (2010) 0.79
Endogenous plasma estradiol in healthy men is positively correlated with cerebral cortical serotonin 2A receptor binding. Psychoneuroendocrinology (2010) 0.79
Cerebral 5-HT2A receptor binding is increased in patients with Tourette's syndrome. Int J Neuropsychopharmacol (2006) 0.79
Serotonin transporters in dopamine transporter imaging: a head-to-head comparison of dopamine transporter SPECT radioligands 123I-FP-CIT and 123I-PE2I. J Nucl Med (2010) 0.79
Neural markers of negative symptom outcomes in distributed working memory brain activity of antipsychotic-naive schizophrenia patients. Int J Neuropsychopharmacol (2012) 0.79
Cortical and subcortical 5-HT2A receptor binding in neuroleptic-naive first-episode schizophrenic patients. Neuropsychopharmacology (2008) 0.78